Digbi Health Introduces Industry-First Medically Managed Weight Loss Program that Leverages Precision Biology to Improve GLP-1 Drug Effectiveness, Adherence, and Tapering
/PALO ALTO, Calif.--(BUSINESS WIRE)--Digbi Health expands its award-winning multi-condition telehealth platform with the introduction of a comprehensive solution that leverages genetic insights, gut microbiome analysis, and continuous glucose monitors (CGMs) to improve the effectiveness of GLP-1 drugs and guarantee successful medication tapering.
Key Features of Digbi Health’s Medically Managed Program:
Comprehensive GI Health Screening and Care: The program offers in-depth GI clinical assessments, tracking, and at-home gut microbiome testing to address GI adverse effects that impact the adherence and effectiveness of GLP-1s.
Personalized Treatment: Digbi uses GLP-Fit (tm) to determine the best treatment path and delivers personalized care. The program provides AI-supported real-time nutritional guidance to improve muscle and glucose health.
Convenience and adaptability: Patients can access their existing physicians or access Digbi Health’s telehealth platform for GLP-1 prescriptions and clinical care. The program accommodates both branded and compounded GLP-1 drugs, ensuring tailored care to meet the needs of employers, physicians, and patients.
“At Digbi Health, we leverage the gut microbiome to boost the body’s natural production of GLP-1, enabling patients to taper off medication while maintaining their health and weight loss,” said Ranjan Sinha, CEO of Digbi Health. “Our ability to combine obesity, GI, and cardiometabolic care into a single platform simplifies management for employers, increases care utilization, and reduces ER visits.”